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Thalidomide is an e¡ective treatment for several in£am-
matory and autoimmune disorders including erythema
nodosum leprosum, Behcet’s syndrome, discoid lupus
erythematosus, and Crohn’s disease. Thalidomide is be-
lieved to exert its anti-in£ammatory e¡ects, at least in
part, by inhibiting tumor necrosis factor-a (TNF-a) pro-
duction by monocytes.We studied the e¡ects of thalido-
mide on epidermal Langerhans cells (LC). LCs are
epidermal antigen-presenting dendritic cells that play
important roles in skin immune responses. Using the
murine epidermis-derived dendritic cell lines, XS106A
from A/J mice and XS52 from BALB/c mice as sur-
rogates for LC, we found that thalidomide inhibited
TNF-a production in a concentration-dependent manner.
Northern blot analysis revealed that thalidomide signi¢-
cantly decreased the peak-induced mRNA level of TNF-
a in XS106A cells and XS52 cells.We then examined the
e¡ect of thalidomide on fresh LC enriched to B98%
using positive selection of Iaþ cells with antibodies con-
jugated to magnetic microspheres. TNF-a production
was reduced by 67.7% at a thalidomide concentration of
200 lg per mL. Thalidomide also had a profound inhi-
bitory e¡ect on the ability of LC to present antigen to a
responsive TH1 clone.Thalidomide inhibits TNF-a pro-
duction and the antigen-presenting ability of epidermal
LCs.These mechanisms may contribute to the therapeu-
tic e¡ects observed with this agent. Key words: skin/den-
dritic cells/cytokines J Invest Dermatol 121:1060 ^1065, 2003
T
halidomide (a-phthalimidoglutarimide), a synthetic
derivative of glutamic acid, whose history includes
great infamy owing to its teratogenicity as well as
the discovery of dramatic therapeutic e⁄cacy in
erythema nodosum leprosum (Sheskin, 1965), has
recently emerged as an interesting immunomodulatory agent
(Corral and Kaplan, 1999). It has been found to be e¡ective in
various in£ammatory or autoimmune diseases (Tseng et al, 1996;
Marriott et al, 1999), including discoid lupus erythematosus
(Duong et al, 1999), Behcet’s syndrome (Hamuryudan et al, 1998),
chronic graft-versus-host disease (Vogelsang et al, 1992), and
Crohn’s disease (Present et al, 1999). It has also been shown to be
e¡ective in cachexia and aphthous ulcers associated with HIV in-
fection (Poli and Fauci, 1992; Paterson et al, 1995). More recently,
there has been great interest in thalidomide for the treatment of
various malignant tumors including multiple myeloma (Singhal
et al, 1999) and high-grade glioma (Fine et al, 2000). The antitu-
mor e¡ect of thalidomide has been largely attributed to its anti-
angiogenesis e¡ect as described (D’Amato et al, 1994), although the
exact mechanisms are still unclear.
The mechanisms of action of thalidomide on the immune sys-
tem have just begun to be understood (Corral et al, 1999). Kaplan
and colleagues have shown that thalidomide inhibits tumor ne-
crosis factor-a (TNF-a) production in stimulated human periph-
eral monocytes (Sampaio et al, 1991) and this inhibitory action
was thought to be due to enhancement of TNF-amRNA degra-
dation (Moreira et al, 1993). They further reported that thalido-
mide acts as a costimulatory signal for T cell activation in vitro
with increased production of interleukin (IL)-2, IL-12, and inter-
feron-g (IFN-g) (Haslett et al, 1998). The increased IL-12 produc-
tion was associated with the upregulation of CD40L on T cells
(Corral et al, 1999). Other postulated mechanisms of action may
include inhibition of chemotaxis of polymorphonuclear cells
(Faure et al, 1980) and decreased monocyte phagocytosis (Barnhill
et al, 1984).
There is a considerable body of evidence demonstrating that
Langerhans cells (LC) and other dendritic cells play important
roles in immunoregulation, host immune defense, and tumor
immunity (Banchereau and Steinman, 1998). LCs are derived
from CD34þ hematopoietic progenitor cells in the bone marrow
(Katz et al, 1979). Caux et al (1992) demonstrated that culturing of
CD34þ hematopoietic progenitor cells with graulocyte^macro-
phage colony-stimulating factor (GM^CSF) and TNF-a resulted
in the production of cells with characteristics of LCs. LCs resid-
ing in the epidermis are immature cells by a number of criteria.
They mature and become more potent T cell stimulators when
they are cultured in vitro for several days. Bacterial products,
cytokines, and growth factors can a¡ect the maturation process
(Schuler and Steinman,1985). LC-containing epidermal cells, when
pulsed with soluble proteins, were able to elicit an antigen-speci-
¢c, proliferative in vitro response in T cells (Stingl et al, 1978,
1981). LCs have been implicated in the development of contact
hypersensitivity (Ptak et al, 1980; Sullivan et al, 1986) and are cap-
able of inducing antitumor immunity (Grabbe et al, 1995a).
Furthermore, murine epidermal LCs have been shown to inter-
nalize Leishmania major and stimulate a parasite-speci¢c T cell re-
sponse (Moll et al, 1993). In this study, we addressed the e¡ect of
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thalidomide on cytokine production and the antigen-presenting
capability of LCs.
MATERIALS AND METHODS
Reagents Thalidomide (Andrulis Research Corporation, Beltsville,
MD) was dissolved in dimethyl sulfoxide (DMSO) to make a 50 mg
per mL stock solution. Murine IL-2 was obtained from Chemicon
International (Temecula, CA). ELISA kits for TNF-a (Quantikine M)
were purchased from R & D Systems (Minneapolis, MN). Reagents for
ELISA of IFN-g were purchased from PharMingen (San Diego, CA).
Mice Female BALB/c (H-2d) and A/J (H-2a) mice between 8 and 12
weeks of age were purchased from the Jackson Laboratory (Bar Harbor,
ME) and were used for the preparation of epidermal cells and the
puri¢cation of LCs. These mice were maintained in the Weill Medical
College of Cornell University animal facility. All procedures were
performed with the consent of the Institutional Animal use and care
Committee.
Media and cell lines RPMI 1640 was supplemented with 10% heat-
inactivated fetal bovine serum (Life Technologies, Grand Island, NY),
100 U/mL penicillin, 100 mg/mL streptomycin, 0.1 mM essential and
nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate,
and 10 mM HEPES bu¡er. ‘‘Complete medium’’ was employed in these
experiments.
The XS52 and XS106A cell lines were gifts from A. Takashima
(University of Texas Health Science Center of Dallas, Dallas, TX). They
were derived from BALB/c (H-2d) and A/J (H-2a) neonatal epidermis,
respectively (Xu et al, 1995a, b), XS cells were propagated in complete
medium containing 1 ng per mL recombinant GM^CSF (Biosource,
Camarillo, CA) and NS cell supernatant as described (Xu et al, 1995a).
The HDK-1 cell line is a keyhole limpet hemocyanin (KLH)-speci¢c
CD4þ Th1 clone (Simon et al, 1990). These cells were cultured every
4 wk, with KLH-pulsed spleen cells and expanded by culturing in the
presence of murine IL-2 (200 U/mL). The DO11.1 cell line is a chicken
ovalbumin (cOVA)-speci¢c T^T hybridoma.
Epidermal cell preparation Epidermal cells were prepared by using a
modi¢cation of a standard protocol (Schuler and Steinman, 1985; Granstein
et al, 1987). Brie£y, truncal skins of shaved and chemically depilated (Neet;
Whitehall Laboratories, NewYork, NY) mice were removed and depleted
of subcutaneous fat and panniculus carnous. The skins were £oated dermis
side down on 0.5 U dispase per milliliter (Boehringer Mannheim,
Indianapolis, IN), and 0.38% trypsin (Sigma Chemical Co., St. Louis,
MO) in Ca2þ/Mg2þ -free phosphate-bu¡ered saline for 40 min at 371C.
Epidermal sheets were collected, washed, and dissociated in Hanks’
balanced salt solution supplemented with 2% heat-inactivated fetal bovine
serum for 20 min at room temperature under continuous gentle agitation.
The resulting cells were then ¢ltered through nylon gauze (Nytex, Tetko,
Elmsford, NY) and washed in Hanks’ balanced salt solution with 2% fetal
bovine serum. Dead cells were removed by treatment with 0.05% trypsin
and 80 mg/mL DNase (Sigma Chemical Co.) in Ca2þ/Mg2þ -free
phosphate-bu¡ered saline for 4 min at room temperature. For preparation
of epidermal cells enriched for LCs, Thy-1-bearing cells were deleted by
incubation with anti-Thy 1.2 monoclonal antibody solution for 30 min
on ice followed by washing and subsequent incubation in low toxicity
rabbit complement (VWR Scienti¢c, Piscataway, NJ) for 30 min at 371C.
Dead cells were removed as described above.
LC puri¢cation The epidermal cell population enriched for LCs was
incubated with 200 mL of anti-Iad antibody (PharMingen) on ice for
30 min followed by washing and subsequent incubation with Dynabeads
M-450 coated with goat anti-mouse IgG (Dynal AS, Oslo, Norway) at 41C
on a rotator for 15 min. The Iaþ LC were then puri¢ed through washing
with phosphate-bu¡ered saline 8 to 10 times using the Dynal MPC-2
magnetic particle concentrator (Dynal AS). The puri¢ed LCs were
analyzed through FACScan (Becton Dickinson, Mountain View, CA) to
determine the purity of the LC population.
ELISA Culture supernatants were harvested at indicated times. After
removal of particulate material by centrifugation, supernatants were
frozen immediately at ^801C. They were quickly thawed and assayed
using an ELISA kit for TNF-a (Quantikine M, R & D Systems) as
described by the manufacturer. For ELISA of IFN-g, plates were coated
with rat anti-mouse IFN-g monoclonal antibody (4 mg/mL) in binding
solution (0.1 M Na2HPO4, pH 9.0) overnight at 41C, and then they were
washed with 0.05% Tween 20 in phosphate-bu¡ered saline, and blocked
with blocking bu¡er (1% bovine serum albumin in phosphate-bu¡ered
saline solution) at room temperature for 1 h. The plates were washed, and
then supernatants and IFN-g standards were added and incubated for 2 h at
room temperature. After being washed, avidin^horseradish peroxidase
conjugate was added at 1:1000 dilution and incubated for 1 h, followed by
color development with ABTS substrate solution. The plates were read
using microplate reader at 410 nm.
Northern blot analysis Total cellular RNA from stimulated XS106A
cells was extracted using the guanidinium thiocyanate^phenol^
chloroform method. The RNA (25 mg) was separated on formaldehyde
agarose gels and transferred to nitrocellulose membranes (Amersham,
Piscataway, NJ) in the presence of 20 SSC overnight. The membranes
were cross-linked by ultraviolet radiation and then were incubated with
prehybridization solution (50% formamide, 5 SSC, 5Denhardt’s
solution, 0.05 M NaHPO4, pH 7.0, 0.5% SDS, 5 mM EDTA, pH 8.0,
100 mg/mL heat-denatured salmon sperm DNA (Sigma Chemical Co.),
and 10% dextran sulfate) overnight at 421C. Then they were incubated
with solution containing 106 cpm per mL 32P-labeled cDNA random-
primed probes for mouse TNF-a (gift of A. Ding at Weill Medical
College of Cornell University) and b-actin overnight at 421C. The
membranes were washed once with 2 SSC and 0.1% SDS at 421C for
15 min, washed once with the same solution at 551C for 15 min, and
washed once with 0.2 SSC and 0.1% SDS at 501C for 15 min. The
blots were exposed to X-ray ¢lm and developed in a Kodak X-Omat
processor. The radioactivity was determined by scanning the gel with a
FUJIX BAS1000 Bio-Imaging analyzer.
DO11.1 assay Epidermal cells were prepared from 8-wk-old BALB/c
mice as described above. Then they were plated in 96-well round-bottom
plates at di¡erent concentrations.They were pretreated with thalidomide or
DMSO alone as control for 24 h; cOVAwas then added to each well and
incubated for 24 h. Then the cells were washed extensively to remove
cOVA and thalidomide. The cOVA-speci¢c T^T hybridoma DO11.1 cells
(Shimonkevitz et al, 1984) were added to the treated epidermal cells and
incubated for an additional 24 h. The supernatants were then harvested
and incubated with CTLL-2 cells for 12 h. The CTLL-2 is an IL-2-
responsive cell line (Grabbe et al, 1995b). Therefore, the IL-2 content of
the supernatant can be measured using CTLL-2 proliferation assay.
Recombinant IL-2 was used as standard. The cells were pulse-labeled
with [3H]thymidine. Incorporation of [3H]thymidine was assessed using a
scintillation counter.
HDK assay LCs were prepared as described above. They were then
treated with thalidomide at di¡erent concentrations: 10, 25, 50, 100, and
200 mg per mL or diluent alone. KLH was added at a ¢nal concentration
of 100 mg per mL. They were incubated for 24 h. Then the cells were
washed three times to remove KLH and thalidomide. After irradiation at
3000 rad (770 rad/min for 3.8 min), they were plated at 1105 cells per well
in complete medium containing 50 mM b-mercaptoethanol in 96-well
round-bottom plates. HDK-1 cells were added at 5104 cell per well.
LCs alone and HDK-1 cells alone were used as negative controls. After
coincubation for 48 h, supernatants were collected and stored at ^201C for
ELISA of IFN-g.
Statistical analysis Statistical di¡erences among groups were
determined using Excel software (Microsoft, Redmond, WA) and tested
by the two-tailed Student’s t test for independent samples. The regression
analysis of variance (ANOVA) was computed using Statview (Abacus
Concepts, Inc., Berkeley, CA). Mean values were considered to be
signi¢cantly di¡erent when po0.05.
RESULTS
Thalidomide inhibits TNF-a production in XS106A and
XS52 cells The dendritic cell-like cell lines, XS106A and
XS52, were derived from newborn A/J and BALB/c mouse
epidermis, respectively. They exhibit many characteristics of LCs
including antigen presentation and cytokine production (Xu et al,
1995a, b). Here we used these two cell lines as surrogates for LCs.
Five million XS106A cells were treated with thalidomide at
various concentrations before stimulation with lipopolysaccharide
(LPS). Supernatants were collected at di¡erent time points, and
the concentration of TNF-a was determined by ELISA. The
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release of TNF-a protein was greatly increased after 3 h of LPS
stimulation. TNF-a content of supernatants peaked after 9 h of
LPS stimulation and then declined (Fig 1). The maximal level of
TNF-awas 17.9 ng per mL (in total of 3 mL) produced by 5106
XS106A cells. We observed a concentration-dependent inhi-
bition of TNF-a production by thalidomide, with maximum
inhibition by 40.1% at thalidomide concentration of 200 mg per
mL at 3 h after LPS stimulation (Fig 1). The di¡erences were
statistically signi¢cant (po0.0001) at all concentration levels at 3,
9, and 21 h after LPS stimulation. Repeated-measures ANOVA
with concentration as a grouping factor and time as the repeated
measure showed signi¢cant e¡ects of both concentration
(F¼ 84.6, po0.001) and time (F¼ 582.6, po0.001).
Thalidomide also inhibits TNF-a production concentration
dependently in XS52 cells (Fig 2), with 31.6% reduction at a
thalidomide concentration of 50 mg per mL, 33.8% reduction at
100 mg per mL, and 57.7% at 200 mg per mL.The di¡erences were
statistically signi¢cant at all concentration levels (po0.01)
To examine the possibility of a toxic e¡ect of thalidomide on
cell viability, XS52 cells were treated with thalidomide at 0, 50,
100, or 200 mg per mL or DMSO alone as a control for 16 h,
and then they were stained with propidium iodide for the
identi¢cation of dead cells. The proportion of propidium iodide-
positive cells was similar in all four groups (B17%). Therefore,
thalidomide did not have a toxic e¡ect on XS52 cells under
these conditions.
We also observed that thalidomide a¡ected cytokine pro-
duc-tion at lower concentrations (Fig 3). The TNF-a level was
reduced by 20.1% at thalidomide of 10 mg per mL (po0.01),
25.1% at 20 mg per mL (po0.05), and 45.6% at 50 mg per mL
(po0.001). Interestingly, thalidomide enhanced IL-12 p40
production with a 50.2% increase at 50 mg per mL (po0.01). In
contrast, IL-6 production was not signi¢cantly a¡ected (data not
shown).
Thalidomide inhibits TNF-a production in puri¢ed fresh
LC To test the e¡ect of thalidomide on epidermal LCs
directly, we ¢rst incubated epidermal cells with anti-Ia antibody,
followed by washing and incubation with goat anti-mouse IgG-
coated magnetic beads to purify Iaþ LC. After repeated washing
and concentration using a magnetic concentrator, Iaþ LCs were
puri¢ed to B98% purity as determined by FACS analysis (data
not shown). Fresh LCs (4105 cells) were then cultured in
complete medium in the presence of GM^CSF at 10 U per mL.
They were pretreated with thalidomide and then stimulated with
LPS.We found that at a thalidomide concentration of 200 mg per
mL,TNF-a protein level was reduced by 67.7% after 12 h of LPS
stimulation (po0.01) and 47% after 21 h of LPS stimulation
(po0.001) (Fig 4). This result is consistent with the ¢ndings
seen in the XS106A and XS52 cells.
Thalidomide treatment decreased the mRNA level of
TNF-a in XS106A cells Northern blot analysis was employed
to determine the e¡ect of thalidomide on TNF-a mRNA level
(Fig 5). TNF-a mRNA peaked about 1 to 3 h after LPS
stimulation and then declined. Thalidomide treatment caused a
49.9% reduction of the mRNA level of TNF-a at 1 h after LPS
stimulation.Therefore, we conclude that at least part, if not all, of
the reduction of TNF-a protein seen with thalidomide is due to
e¡ects on mRNA.
Thalidomide inhibits the antigen-presenting abilities of LC
We further explored the e¡ect of thalidomide on the antigen-
Figure1. E¡ect of thalidomide on TNF-a production in LPS-sti-
mulated XS106A cells. A total of 5106 XS106A cells were treated with
thalidomide at various concentrations (50, 100, or 200 mg/mL) or DMSO
before stimulation with LPS. Supernatants were collected at di¡erent time
points (3, 9, and 21 h). Data represent TNF-a concentration in the super-
natants, expressed as averages7SD from triplicates in one experiment. Sta-
tistical analysis shows the di¡erence in the amount TNF-a production is
signi¢cant at all concentration levels and at all time points tested,
po0.001 compared to no thalidomide.
Figure 2. Inhibition of TNF-a production by thalidomide in LPS-
stimulated XS52 cells. A total of 5105 XS52 cells were treated with
thalidomide at various concentrations (50, 100, or 200 mg/mL) or DMSO.
Supernatants were taken out at 9 h after LPS stimulation. Data represent
the concentration of TNF-a in the supernatants, expressed as averages7SD
from triplicates in one experiment. po0.01 for no thalidomide versus all
other groups.
Figure 3. Inhibition of TNF-a production and increase of IL-12
production by thalidomide in LPS-stimulated XS52 cells at low
concentrations. A total of 3105 cells were treated with thalidomide at
various concentrations (10, 20, or 50 mg/mL) or DMSO for 12 h. Superna-
tants were taken out at 9 h after LPS stimulation. Data represent the con-
centration of TNF-a, IL-12 p40 subunit in the supernatants, expressed as
averages7SD from triplicates in one experiment. po0.05 for no thalido-
mide vs. thalidomide.
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presenting abilities of LCs. DO11.1 cells respond to presentation
of cOVA presented by I-Ad with production of IL-2. In this
experiment, epidermal cells were treated with cOVA and with
or without the presence of thalidomide. These cells were then
washed extensively to remove these substances. They were
incubated with DO11.1 cells. Production of IL-2 was assessed by
measuring [3H]thymidine incorporation by the IL-2-dependent
T cell clone, CTLL-2. In the absence of IL-2, very little
[3H]thymidine was incorporated. Supernatants from DO11.1 cell
alone caused small amount of [3H]thymidine uptake (1558.27þ
24.54 cpm). Incubation of DO11.1 cells with increasing numbers
of epidermal cells preincubated with cOVA resulted in increasing
stimulation of DO11.1 cells. Preincubation of epidermal cells with
thalidomide signi¢cantly decreased their ability to stimulate
DO11.1 cells (po0.001, Fig 6).
Presentation of antigen to a T cell clone (Fig 7) was used as
a second assay to investigate the e¡ect of thalidomide on the
antigen-presenting ability of LCs. In these experiments, LCs
enriched to 495% homogeneity by antibodies linked to
Dynabeads, as described above, were employed. Puri¢ed LCs
(1105 cells) were treated with thalidomide and KLH, followed
by coincubation with HDK-1 cells (5  104 cells). LCs were able
to present KLH to HDK-1 cells and therefore stimulate them to
produce IFN-g. IFN-g produced by HDK-1 cells alone without
antigen-presenting cells or LCs alone was negligible. In the
presence of KLH-treated LCs, HDK-1 cells were activated and
produced a large amount of IFN-g. Thalidomide treatment of
LCs inhibited production of IFN-g by HDK-1 cells in a
concentration-dependent manner, with maximum reduction of
62.3% at thalidomide concentration of 200 mg per mL (po0.001).
There was also a statistically signi¢cant inhibition of IFN-g
Figure 4. Inhibition of TNF-a production by thalidomide in puri-
¢ed LC. Puri¢ed LC (4  105 cells/well) were treated with thalidomide at
200 mg per mL or DMSO as control for 24 h. Supernatants were taken out
at 12 and 21 h after LPS administration. Data represent TNF-a concentra-
tion in the supernatants, expressed as averages7SD from triplicates in one
experiment. po0.01 for both 12 and 21 h.
Figure 5. The e¡ect of thalidomide onTNF-a mRNA level in LPS-
stimulated XS106A cells as analyzed by northern blot hybridiza-
tion. Total RNA (25 mg) from XS106A cells treated with thalidomide
(200 mg/mL) for 48 h and stimulated with LPS for 1, 3, 6, and 9 h was
probed for TNF-a and b-actin. Autographs were exposed for 4 h for
TNF-a and 2 h for b-actin.
Figure 6. The e¡ect of thalidomide on the immunostimulatory
function of epidermal LC as determined by DO11.1 assay. Epidermal
cells (EC) at di¡erent concentrations (0, 0.5  105, 1105, and 2105)
were pretreated with thalidomide (200 mg/mL) or DMSO for 24 h. Then
they were incubated with cOVA for 24 h. Cells were washed and then co-
incubated with DO11.1 cells for 24 h. Supernatants were collected and in-
cubated with CTLL-2 cells. The incorporation of [3H]thymidine by
CTLL-2 cells was measured by scintillation counter. Results represent aver-
ages7SD of triplicates. po0.001.
Figure 7. The e¡ects of thalidomide on the immunostimulatory
function of epidermal LC as determined by HDK assay. Enriched
LLs were preincubated with KLH, thalidomide at various concentrations
(10, 25, 50, 100, or 200 mg/mL), or DMSO as control for 24 h. After they
were washed, 1105 ECs were coincubated with 5  104 HDK cells for
48 h. The amount of IFN-g in the supernatants was measured by ELISA
assay. HDK cells alone and LCs alone were used as negative controls. Re-
sults represent averages7SD of triplicates. po0.05 for 0 vs. 10 mg per mL;
po0.001 for 0 vs. all other thalidomide groups.
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production even at low thalidomide concentrations, 22.2%
reduction at 10 mg per mL (p¼ 0.02) and 38.5% reduction at
25 mg per mL (po0.001).
To investigate whether thalidomide might inhibit T cell
activity directly, HDK cells were treated with thalidomide at 10,
25, 50, 100, and 200 mg per mL overnight. They were washed and
added to EC cells that had been preincubated with KLH for 24 h.
After 18 h of incubation, supernatants were collected to evaluate
IFN-g production by ELISA.We found that thalidomide did not
inhibit the production of IFN-g by HDK cells (Fig 8).
The e¡ects of thalidomide on LC expression of Ia and some
costimulatory molecules were tested on enriched epidermal cells,
XS52 and XS106A cells. Cells were stimulated with GM^CSF
(50 mg/mL) or LPS (0.1 or 1 mg/mL), with or without the
presence of thalidomide at 100 mg per mL. Cells were then
stained with anti-Iad, CD80, CD86, and CD54 and analyzed by
FACS analysis. No signi¢cant changes were noticed (data not
shown).
DISCUSSION
LCs play an essential role in skin immune responses. In this arti-
cle, we report that thalidomide inhibits TNF-a production in
dendritic cell lines (XS106A and XS52) and fresh puri¢ed LC. It
also inhibits the T cell-stimulating function of LCs. Therefore, in
addition to its inhibitory e¡ect on monocytes (Sampaio et al,
1991) and costimulatory e¡ect onTcells (Haslett et al, 1998), thali-
domide exhibits inhibitory activity on LCs. The combination of
these e¡ects may contribute to the immunomodulating proper-
ties of this drug.
TNF-a is a pleiotropic cytokine, produced primarily by
monocytes and macrophages, which plays an important role in
host immune responses. It acts on many cell types including en-
dothelial cells, leukocytes, and ¢broblast. Dysregulation of TNF-
a may contribute to the pathogenesis of diseases, such as acute
in£ammation in erythema nodosum leprosum, and tuberculosis
meningitis, tissue destruction in rheumatoid arthritis, cachexia
in AIDS and cancer patients, and septic shock. Reduction of the
serum level of TNF-a correlates well with the clinical improve-
ment of patients with evidence of an elevated TNF-a level asso-
ciated with their disease state, such as erythema nodosum
leprosum (Sampaio et al, 1993), AIDS (Lahdevirta et al, 1988), and
tuberculosis (Tramontana et al, 1995).
Recent studies have shown that TNF-a plays an important role
in the promotion of LC maturation (Caux et al, 1992) and antigen
presentation (Grabbe et al, 1992). TNF-a is also a stimulator for
the migration of LCs (Cumberbatch et al, 1999). Deletion of
TNF receptor resulted in depressed LC migration and reduced
contact hypersensitivity response (Wang et al, 1997). In contrast,
LCs can produce large amounts of TNF-a in the presence of sti-
muli. Taken together,TNF-a may act in a paracrine and autocrine
fashion in the regulation of LC functions. Therefore, the inhibi-
tory e¡ect of thalidomide on LC function may be at least partly
mediated by reduction in TNF-a expression. This hypothesis is
currently being tested.
Immunosuppressive agents have direct e¡ects on epidermal
LCs as well. Furue and Katz (1989) showed that dexamethasone
decreased the number of Iaþ LCs and also inhibited the immu-
nostimulatory function of LC in vitro. In vivo application of
dexamethasone on mouse ears caused decreased Iaþ cells in
dexamethasone-treated skin (Grabbes et al, 1995b). Kitajima et al
(1996) showed that steroids could a¡ect the T cell-mediated term-
inal maturation of a dendritic cell line. Cyclosporine has also
been shown to inhibit epidermal LC immunostimulatory func-
tion, in addition to its inhibitory e¡ects on lymphocytes (Furue
and Katz, 1988; Teunissen et al, 1991).
Thalidomide does not exhibit systemic immunosuppression as
in the case of glucocorticosteroids and cyclosporine. Although all
of these agents have inhibitory e¡ects on the function of LC/den-
dritic cells, thalidomide has a costimulatory e¡ect on activated T
cells, whereas both glucocorticosteroids and cyclosporine have
profound inhibitory e¡ect on T cells. Thalidomide signi¢cantly
enhanced IL-12 production at 50 mg per mL. At 10 mg per mL, a
slight but nonsigni¢cant decrease in IL-12 production was ob-
served. The immunomodulatory e¡ect of thalidomide without
induction of marked systemic immunosuppression may provide
a unique position in the management of in£ammatory and auto-
immune conditions. Although it was approved by FDA for the
treatment of erythema nodosum leprosum in 1998, its current
use is under strict control because of its side e¡ect pro¢le. The
development of thalidomide analogs with more potent anti-
TNF-a activity and fewer side e¡ects may have potential as a
new class of immune modulators (Marriott et al, 1998).
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